Blinatumomab Redirects Donor Lymphocytes against CD19(+) Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation

Blinatumomab alone or with donor leukocyte infusions (DLI) has been used after allogeneic hematopoietic stem cell transplantation (HSCT) as a salvage therapy in relapsing patients with CD19(+) hematological malignancies. It was effective in a fraction of them, with low incidence of Graft-versus-Host...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancusi, Antonella, Zorutti, Francesco, Ruggeri, Loredana, Bonato, Samanta, Tricarico, Sara, Zei, Tiziana, Iacucci Ostini, Roberta, Viglione, Valerio, Sembenico, Rebecca, Sciabolacci, Sofia, Cardinali, Valeria, Martelli, Massimo Fabrizio, Mecucci, Cristina, Carotti, Alessandra, Martelli, Maria Paola, Velardi, Andrea, Pierini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671266/
https://www.ncbi.nlm.nih.gov/pubmed/38003295
http://dx.doi.org/10.3390/ijms242216105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671266/
https://www.ncbi.nlm.nih.gov/pubmed/38003295
http://dx.doi.org/10.3390/ijms242216105

Ejemplares similares